Table 1 Baseline Characteristics for the ablation groups
|  | MWA (N = 81) | RFA (N = 140) | Total (N = 221) | P-value |
|---|---|---|---|---|
Age, years | Â | Â | Â | 0.81 |
 Mean ± SD | 68.5 ± 8.1 | 67.6 ± 10.4 | 67.9 ± 9.6 |  |
Gender, no. (%) | Â | Â | Â | 0.0822 |
 Female | 23 (28.4%) | 56 (40%) | 79 (35.7%) |  |
 Male | 58 (71.6%) | 84 (60%) | 142 (64.3%) |  |
Cirrhosis, no. (%) | Â | Â | Â | 0.522 |
 No | 5 (6.2%) | 12 (8.6%) | 17 (7.7%) |  |
 Yes | 76 (93.8%) | 128 (91.4%) | 204 (92.3%) |  |
Underlying Liver Disease, no. (%) | Â | Â | Â | 0.142 |
 Hepatitis C virus | 27 (33.3%) | 56 (40%) | 83 (37.6%) |  |
 Non-alcoholic fatty liver | 26 (32.1%) | 25 (17.9%) | 51 (32.1%) |  |
 Alcoholic Liver disease | 12 (14.8%) | 22 (15.7%) | 34 (15.4%) |  |
 Hepatitis B virus | 5 (6.2%) | 7 (5%) | 12 (5.4%) |  |
 Others | 11 (13.6%) | 30 (21.4%) | 41 (18.6%) |  |
Portal Hypertension, no. (%) | Â | Â | Â | 0.662 |
 No | 30 (37%) | 56 (40%) | 86 (38.9%) |  |
 Yes | 53 (65.4%) | 97 (61.4%) | 188 (63.7%) |  |
Child Pugh score, no. (%) | Â | Â | Â | 0.52 |
 A | 58 (71.6%) | 106 (75.7%) | 164 (74.2%) |  |
 B | 23 (28.4%) | 34 (24.3%) | 57 (25.8%) |  |
Tumor Size | Â | Â | Â | 0.511 |
 Mean ± SD | 2.2 ± 0.6 | 2.3 ± 1.2 | 2.3 ± 1 |  |
Tumors Number, no. (%) | Â | Â | Â | 0.0121 |
 = 1 | 66 (81.5%) | 96 (68%) | 162 (73.3%) |  |
 = 2 | 10 (12.3%) | 29 (20.7%) | 39 (17.6%) |  |
 = 3 | 4 (4.9%) | 8 (5.7%) | 12 (5.4%) |  |
 > 3 | 1 (1.2%) | 7 (5%) | 8 (3.7%) |  |
BCLC Staging, no. (%) | Â | Â | Â | 0.00082 |
 0 | 2 (2.5%) | 15 (10.7%) | 17 (7.7%) |  |
 A | 77 (95.1%) | 105 (75%) | 182 (82.4%) |  |
 B | 2 (2.5%) | 20 (14.3%) | 22 (10%) |  |
Hyperlipidemia, no. (%) | Â | Â | Â | 0.0222 |
 No | 55 (67.9%) | 114 (81.4%) | 169 (76.5%) |  |
 Yes | 26 (32.1%) | 26 (18.6%) | 52 (23.5%) |  |
Hypothyroidism, no. (%) | Â | Â | Â | 0.732 |
 No | 65 (81.5%) | 115 (82.1%) | 180 (81.4%) |  |
 Yes | 16 (19.8%) | 25 (17.9%) | 41 (18.6%) |  |
AFP | Â | Â | Â | 0.261 |
 Mean ± SD | 44.3 ± 118.9 | 84.7 ± 329.9 | 70.1 ± 273.4 |  |
Cholesterol (mg/dl) | Â | Â | Â | 0.691 |
 Mean ± SD | 152.7 ± 34.7 | 154.7 ± 69.9 | 154.1 ± 61.3 |  |
Triglycerides (mg/dl) | Â | Â | Â | 0.31 |
 Mean ± SD | 107.8 ± 46 | 107.2 ± 70.3 | 107.4 ± 63.8 |  |
HDL (mg/dl) | Â | Â | Â | 0.911 |
 Mean ± SD | 47.7 ± 18.9 | 48.1 ± 16.3 | 48 ± 17 |  |
LDL (mg/dl) | Â | Â | Â | 0.891 |
 Mean ± SD | 83.0 ± 30.8 | 82.4 ± 33.2 | 82.6 ± 32.3 |  |
Glucose (mg/dl) | Â | Â | Â | 0.771 |
 Mean ± SD | 104.7 ± 47.2 | 109 ± 50.4 | 107.9 ± 49.5 |  |
HB A1c | Â | Â | Â | 0.31 |
 Mean ± SD | 6.3 ± 1 | 6.9 ± 1.7 | 6.8 ± 1.6 |  |
Pre-ablation Monocytes×109/L |  |  |  | 0.0111 |
 Mean ± SD | 0.6 ± 0.3 | 0.6 ± 0.3 | 0.6 ± 0.3 |  |
Pre-ablation Lymphocyte× 109/L |  |  |  | 0.191 |
 Mean ± SD | 1.5 ± 0.8 | 1.3 ± 0.7 | 1.4 ± 0.7 |  |
Post-ablation Lymphocyte× 109/L |  |  |  | 0.831 |
 Mean ± SD | 1.2 ± 0.7 | 1.2 ± 0.6 | 1.2 ± 0.6 |  |
Pre-ablation Neutrophils× 109/L |  |  |  | 0.251 |
 Mean ± SD | 3.4 ± 1.6 | 3.2 ± 1.7 | 3.3 ± 1.7 |  |
Post-ablation Neutrophils× 109/L |  |  |  | 0.161 |
 Mean ± SD | 4.5 ± 3.3 | 3.8 ± 2.8 | 4.1 ± 3 |  |
Pre-ablation NLR | Â | Â | Â | 0.871 |
 Mean ± SD | 2.9 ± 1.8 | 2.9 ± 1.7 | 2.9 ± 1.7 |  |
Post-ablation NLR | Â | Â | Â | 0.821 |
 Mean ± SD | 4.8 ± 6 | 4.4 ± 5.5 | 4.5 ± 5.7 |  |
Pre-ablation Platelets×109/L |  |  |  | 0.331 |
 Mean ± SD | 134.1 ± 75.4 | 123.3 ± 65 | 127.3 ± 69.1 |  |
Pre-ablation PLR | Â | Â | Â | 0.711 |
 Mean ± SD | 104.5 ± 65.2 | 106.1 ± 56.8 | 105.5 ± 59.9 |  |
Pre-ablation LMR | Â | Â | Â | 0.691 |
 Mean ± SD | 2.7 ± 1.6 | 2.7 ± 1.2 | 2.7 ± 1.4 |  |